Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from MarketBeat

Mitchells & Butlers H1 Earnings Call Highlights

Mitchells & Butlers (LON:MAB) said first-half trading remained ahead of the wider market, with management pointing to resilient sales, cost controls and balance sheet progress despite weaker second-quarter momentum and significant inflationary pressures. Chief Executive Officer Phil Urban said

MarketBeat

Smiths Group Q3 Earnings Call Highlights

Smiths Group (LON:SMIN) lowered its full-year organic revenue growth outlook after Middle East-related disruption weighed on its John Crane business in the third quarter, Chief Financial Officer Julian Fagge said on the company’s Q3 2026 trading update call. Fagge said Smiths’ organic revenue was f

MarketBeat

AJ Bell H1 Earnings Call Highlights

AJ Bell (LON:AJB) reported record first-half customer growth and net inflows in its 2026 interim results, with management saying the investment platform performed strongly despite political uncertainty in the U.K. and heightened market volatility linked to the tariff war. The company said platform

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

easyJet H1 Earnings Call Highlights

easyJet (LON:EZJ) said its first-half performance for the period ended March 31, 2026, was in line with expectations and consistent with its April trading statement, while management emphasized that the airline is managing near-term geopolitical and fuel volatility from what it described as a strong

MarketBeat

Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins

Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant depression, while preparing commercially for a potentially accelerated regulatory timel

MarketBeat

Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect

Climb Bio (NASDAQ:CLYM) outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright’s BioConnect Conference, with management emphasizing two biologic drug programs aimed at immune-mediated diseases, including nephrology and hematology indications.

MarketBeat

Charter Communications Eyes Cash Flow Lift as Network Upgrades, Cox Deal Advance

Charter Communications (NASDAQ:CHTR) Chief Financial Officer Jessica Fischer said the company’s top priority remains growing its connectivity business while it works through major investment initiatives, prepares for the integration of Cox assets and seeks to improve free cash flow as capital spendi

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Check Point Software Technologies Eyes Firewall Rebound After Sales Overhaul

Check Point Software Technologies (NASDAQ:CHKP) executives said the company has moved past the most disruptive phase of a broad go-to-market reorganization and expects its firewall product business to return to growth later this year, according to remarks at a JPMorgan software event. The discussio

MarketBeat

CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder cancer, and to discuss upcoming regulatory, manufacturing and commercial milestones. The discussio

MarketBeat

CDW Touts AI Factory Demand, Recurring Revenue Push at JPMorgan Conference

CDW (NASDAQ:CDW) executives said customers are moving beyond artificial intelligence experimentation and are increasingly asking for help deploying AI “safely, economically, and at scale,” during a JPMorgan fireside chat featuring Chair and CEO Christine Leahy and CFO Albert Miralles. Leahy said th

MarketBeat

AEVEX Q1 Earnings Call Highlights

AEVEX (NYSE:AVEX) reported sharply higher first-quarter revenue and profitability in its first earnings call as a public company, citing strong execution on a large unmanned aerial systems program and rising demand for autonomous defense platforms. Chief Executive Officer Roger Wells said the compa

MarketBeat

Urban Outfitters Q1 Earnings Call Highlights

Urban Outfitters (NASDAQ:URBN) reported record first-quarter fiscal 2027 sales and earnings, with management pointing to broad strength across its retail brands, continued growth at Nuuly and a strong wholesale performance. Chief Executive Officer Dick Hayne said net sales rose 11% to $1.5 billion

MarketBeat

StepStone Group Q4 Earnings Call Highlights

StepStone Group (NASDAQ:STEP) reported record fee-related earnings and fundraising in its fiscal fourth quarter 2026, even as GAAP results were weighed down by accounting related to its StepStone Private Wealth profits interests. The private markets investment firm reported a GAAP net loss attribut

MarketBeat

NVIDIA Q1 Earnings Call Highlights

NVIDIA (NASDAQ:NVDA) reported record first-quarter fiscal 2027 results, with revenue, operating income and free cash flow all surpassing prior company highs, as executives said demand for AI infrastructure continued to accelerate across hyperscale cloud providers, AI cloud companies, sovereign custo

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

e.l.f. Beauty Q4 Earnings Call Highlights

e.l.f. Beauty (NYSE:ELF) reported what executives described as a seventh consecutive year of “industry-leading” results, with fiscal 2026 net sales up 25% and adjusted EBITDA up 13%, while also signaling a more cautious near-term outlook for its core e.l.f. brand. Chairman and Chief Executive Offic

MarketBeat

CCC Intelligent Solutions Enters Next AI Phase as Products Scale With Major Customers

CCC Intelligent Solutions Holdings Inc. Common Stock (NASDAQ:CCC) management said the company is entering its next phase with artificial intelligence moving from evaluation and testing into broader production use across its customer base. Speaking at the JPMorgan Boston TMC Conference, CEO Githesh

MarketBeat

Biosig Technologies Q1 Earnings Call Highlights

Biosig Technologies (NASDAQ:STEX), operating as Streamex Corp, said its first quarter of 2026 marked a transition from product preparation to early commercialization, highlighted by the launch of its tokenized gold product, the payment of initial dividends to holders and the retirement of its conver

MarketBeat

Intuit Q3 Earnings Call Highlights

Intuit (NASDAQ:INTU) reported fiscal third-quarter revenue growth of 10% and raised its full-year outlook, while management outlined plans to reduce the company’s full-time workforce by 17% and adjust its approach to lower-income, price-sensitive tax filers. Chairman and CEO Sasan Goodarzi said the

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Belite Bio Q1 Earnings Call Highlights

Belite Bio (NASDAQ:BLTE) said it has begun a rolling New Drug Application submission to the U.S. Food and Drug Administration for Tinlarebant in Stargardt disease, while also accelerating preparations for a potential commercial launch. On the company’s first-quarter 2026 earnings call, Chairman and

MarketBeat

Booking CEO Sees AI, Connected Trips Driving Long-Term Travel Growth

Booking (NASDAQ:BKNG) Holdings CEO and President Glenn Fogel said the online travel company remains focused on long-term product investment and market-share gains, even as the travel industry faces near-term uncertainty from geopolitical conflict and macroeconomic concerns. Speaking at an investor

MarketBeat

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

MarketBeat

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances

Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year. Sp

MarketBeat

CorVel Q4 Earnings Call Highlights

CorVel (NASDAQ:CRVL) said revenue and earnings increased in its March quarter and fiscal 2026, as growth in its Network Solutions business, stronger bookings and operating efficiency helped offset a higher effective tax rate. President and Chief Executive Officer Michael Combs opened the call by sa

MarketBeat

TJX Companies Q1 Earnings Call Highlights

TJX Companies (NYSE:TJX) reported first-quarter fiscal 2027 results that topped its internal expectations, driven by broad comparable sales gains, higher customer transactions and improved margins, executives said on the company’s earnings call. Chief Executive Officer and President Ernie Herrman s

MarketBeat

Mirum Pharma: A Rare Disease Growth Story to Watch

Mirum stock pulled back after earnings despite strong growth. Here’s why investors still see upside in the rare disease biotech company

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.